Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE:RMD) with a price target of $180.
ResMed registered a street-beating performance in the first quarter, where revenue increased by 16% to $1.1 billion.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased